- Home
- PHGE vs APRE Comparison
PHGE vs APRE Comparison
Compare PHGE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- APRE
- Stock Information
- Founded
- PHGE 2015
- APRE 2006
- Country
- PHGE Israel
- APRE United States
- Employees
- PHGE N/A
- APRE N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHGE Health Care
- APRE Health Care
- Exchange
- PHGE Nasdaq
- APRE Nasdaq
- Market Cap
- PHGE 11.0M
- APRE 10.0M
- IPO Year
- PHGE N/A
- APRE 2019
- Fundamental
- Price
- PHGE $0.45
- APRE $1.67
- Analyst Decision
- PHGE Strong Buy
- APRE Strong Buy
- Analyst Count
- PHGE 1
- APRE 2
- Target Price
- PHGE $15.00
- APRE $15.50
- AVG Volume (30 Days)
- PHGE 278.8K
- APRE 25.3K
- Earning Date
- PHGE 08-13-2025
- APRE 08-11-2025
- Dividend Yield
- PHGE N/A
- APRE N/A
- EPS Growth
- PHGE N/A
- APRE N/A
- EPS
- PHGE N/A
- APRE N/A
- Revenue
- PHGE N/A
- APRE $1,284,475.00
- Revenue This Year
- PHGE N/A
- APRE N/A
- Revenue Next Year
- PHGE N/A
- APRE N/A
- P/E Ratio
- PHGE N/A
- APRE N/A
- Revenue Growth
- PHGE N/A
- APRE 33.27
- 52 Week Low
- PHGE $0.34
- APRE $1.41
- 52 Week High
- PHGE $3.86
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- PHGE 51.35
- APRE 40.95
- Support Level
- PHGE $0.34
- APRE $1.77
- Resistance Level
- PHGE $0.51
- APRE $1.91
- Average True Range (ATR)
- PHGE 0.05
- APRE 0.15
- MACD
- PHGE 0.01
- APRE -0.02
- Stochastic Oscillator
- PHGE 77.53
- APRE 22.45
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.